|
Jul 26
|
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
|
|
Jul 25
|
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
|
|
Jul 25
|
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
|
|
Jul 25
|
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
|
|
Jul 23
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024
|
|
Jun 25
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
|
|
Jun 18
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
|
|
Dec 7
|
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
Dec 7
|
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
|
|
Dec 7
|
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
|
|
Oct 23
|
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
|
|
Oct 17
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023
|
|
Jul 21
|
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
|
|
Jul 21
|
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
|
|
Jul 19
|
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
|
|
Jul 18
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023
|